This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log in
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Feb 23;8(1):3520.
doi: 10.1038/s41598-018-21127-0.

Longitudinal change in the serology of antibodies to Chlamydia trachomatis pgp3 in children residing in a trachoma area

Affiliations
Clinical Trial

Longitudinal change in the serology of antibodies to Chlamydia trachomatis pgp3 in children residing in a trachoma area

Sheila K West et al. Sci Rep. .

Abstract

A serologic test for antibodies to chlamydial antigen pgp3 may be a useful tool for trachoma surveillance. However, little is known about the stability of antibody status over time, or factors associated with seroreversion/conversion. A cohort of 2,111 children ages 1-9 years in Tanzania were followed for one year in the absence of mass azithromycin. At baseline and follow-up, they were evaluated for trachoma, chlamydial infection, and antibodies to chlamydial antigen pgp3. At baseline, 31% of children were seropositive for pgp3 antibodies and 6.4% seroreverted to negative over one year. Of those seronegative, 9.8% seroconverted over the year. The seroreverters had lower baseline mean fluorescence intensity (MFI-BG) values compared to the seropositives who remained positive (Odds Ratio = 0.04 for every unit increase in log10MFI-BG, 95% CI = 0.02-0.09), and were more likely to live in communities with trachoma <5% (p < 0.008). While seroconversion was expected, seroreversion was unexpected. The low seroprevalence rate reported from low endemic areas may be due to seroreversion as well as lack of exposure.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Log10 of MFI-BG at baseline and at follow up for the longitudinal cohort, with the red line showing the cut-off for positivity of each distribution.
Figure 2
Figure 2
Log10MFI-BG at baseline for the longitudinal cohort within the four groups according to antibody status at baseline and follow up.
Figure 3
Figure 3
Log10MFI-BG at one year follow up for the longitudinal cohort within the four groups according to antibody status at baseline and follow up.

References

    1. Taylor HR, Burton MJ, Haddad D, West S, Wright H. Trachoma. Lancet. 2014;384:2142–2152. doi: 10.1016/S0140-6736(13)62182-0. - DOI - PubMed
    1. World_Health_Organization. in WHA51.11 (ed World_Health_Assembly) (1998).
    1. World_Health_Organization. Technical Consultation on Trachoma Surveillance. 1–23 (World Health Organization Press Geneva, Switzerland, 2015).
    1. Martin DL, et al. Serology for trachoma surveillance after cessation of mass drug administration. PLoS Negl Trop Dis. 2015;9:e0003555. doi: 10.1371/journal.pntd.0003555. - DOI - PMC - PubMed
    1. Harding-Esch EM, et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Negl Trop Dis. 2013;7:e2115. doi: 10.1371/journal.pntd.0002115. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources

Full text links
Nature Publishing Group full text link Nature Publishing Group Free PMC article
Cite

AltStyle によって変換されたページ (->オリジナル) /